Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 7, 2008

Starpharma and Unilever Enter Co-Development Product Agreement

  • Starpharma signed an agreement with Unilever to codevelop a research tool using Starpharma’s Priostar® dendrimer technology. An undisclosed fee is payable to Starpharma’s U.S. subsidiary, Dendritic Nanotechnologies (DNA), as part of the arrangement.

    DNT will make its Priostar® dendrimers available to Unilever as imaging agents to analyze the microscopic structure of foods. Understanding the microstructure is an important factor in creating appetizing food, determining properties such as mouth-feel and controlled release of taste and smell, explains a Unilever official, who adds that the company’s research and development scientists will use the dendrimers for analysis purposes as part of one of their innovation projects.

    “We are delighted to be working with a company of Unilever’s caliber and resources in this highly innovative application of Priostar® dendrimers. This agreement underscores the relevance of dendrimers across a wide variety of industries.” commented Robert Berry, president of Dendritic Nanotechnologies. “Dendrimers are relevant in the chemicals and materials industries as well as the pharmaceutical and medical sectors.”

    This is the company’s second agreement with a commercial party for applications of Priostar® and it extends Starpharma’s recent commercial arrangements for its dendrimers. These include deals with EMD Chemicals, SSL, and Stiefel Laboratories.